P0211: Characterization of drug-specific CD4+ T cells in patients with inflammatory bowel diseasesECCO'25Year: 2025
Authors: Weichberger, A.(1)*;Rios Martini, G.(1);Namuch Castro , D.M.(1);Funcke, N.(1);Müller, S.(1);Marutz, H.(1);Sokolova, M.(2);Stamer, N.(2);Riffert, J.(2);Bergfeld, A.(2);Schulze Dieckhoff, T.(2);Nikolaus, S.(2);Aden, K.(2);Tran, F.(2);Schreiber, S.(2);Bacher, P.(1);
(1)Christian-Albrechts University, Institute of Immunology, Kiel, Germany;(2)UKSH, Department of Internal Medicine, Kiel, Germany;
P0212: Non-canonical STING signaling in intestinal epithelial cells guides DNA damage-driven stem cell function and protects from intestinal carcinogenesisECCO'25Year: 2025
Authors: Xiang, H.(1)*;Woitaske-Proske, C.(2);Bernardes, J.P.(1);Martini, G.R.(1);Wottawa, F.(1);Bornhaeuser, J.(1);Kakavand, N.(1);Guang, Y.(1);Wu, Q.(1);Kugler, J.(1);Welz, L.(1);Konukiewitz, B.(3);Peifer, C.(2);Schreiber, S.(4);Tschurtschenthaler, M.(5);Rosenstiel, P.(1);Aden, K.(1);
(1)Kiel University, Institute of Clinical Molecular Biology, Kiel, Germany;(2)Kiel University, Institute of Pharmacy, Kiel, Germany;(3)Christian-Albrechts-University and University Hospital Schleswig-Holstein- Campus Kiel, Department of Pathology, Kiel, Germany;(4)Christian-Albrechts-University and University Hospital Schleswig-Holstein- Campus Kiel, Department of Internal Medicine I, Kiel, Germany;(5)Technical University of Munich Klinikum rechts der Isar Center for Translational Cancer Research, Department of Internal Medicine II, Munich, Germany;
1. Reijns, Martin A.M., et al., Enzymatic Removal of Ribonucleotides from DNA Is Essential for Mammalian Genome Integrity and Development. Cell, 2012. 149(5): p. 1008-1022.
2. Bartsch, K., et al., Absence of RNase H2 triggers generation of immunogenic micronuclei removed by autophagy. Hum Mol Genet, 2017. 26(20): p. 3960-3972.
3. Aden, K., et al., Epithelial RNase H2 Maintains Genome Integrity and Prevents Intestinal Tumorigenesis in Mice. Gastroenterology, 2019. 156(1): p. 145-159 e19.
P0213: Salivary Veillonella parvula from Crohn's Disease Patients Exacerbates Intestinal InflammationECCO'25Year: 2025
Authors: Xiang, B.(1);Hu, J.(2);Zhi, M.(1);Xu, Z.(1)*;Zhang, M.(1);Peng, X.(1);
(1)The Sixth Affiliated Hospital of Sun Yat-Sen University, Department of Gastroenterology, Guangzhou- Guangdong, China;(2)The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangdong Institute of Gastroenterology, Guangzhou- Guangdong, China;
P0214: Notch Pathway-Mediated epithelial-mesenchymal transition and Fibrosis in Complicated Crohn’s DiseaseECCO'25Year: 2025
Authors: Patel, J.(1);Cejudo-Garcés, A.(1);Jarén, A.(1)*;Macias-Ceja, D.C.(1);Manresa, M.(2);López, A.(3,4);Cosin-Roger, J.(1,5);Calatayud, S.(1,5);Barrachina, M.D.(1,5);Ortiz-Masiá, D.(5,6,7);
(1)Universitat de València, Pharmacology department, Valencia, Spain;(2)University College Dublin, School of Biomolecular and Biomedical Science, Dublin, Ireland;(3)Universitat de València, Medicina department, Valencia, Spain;(4)Hospital Universitario Doctor Peset, Digestivo, Valencia, Spain;(5)Centro de investigaciones en red CIBER, Enfermedades hepáticas y digestivas, Valencia, Spain;(6)Universitat de València, Medicine department, Valencia, Spain;(7)Grupo español de trabajo en enfermedad de Crohn y Colitis GETECCU, Grupo de investigación básica y traslacional, Madrid, Spain;
M Rodriguez-Antequera, J Cosin-Roger, D Macias-Ceja, P Salvador, L Gisbert-Ferrándiz, S Coll, J Manyé, R Alós, F Navarro-Vicente, S Calatayud, M D Barrachina, D Ortiz-Masia, P041 Differences in NOTCH signalling between stricturing and penetrating behaviour in Crohn’s disease, Journal of Crohn's and Colitis, Volume 13, Issue Supplement_1, March 2019, Page S107, https://doi.org/10.1093/ecco-jcc/jjy222.165
P0215: Food avoidance and symptom triggers in patients with Ulcerative Colitis while in remissionECCO'25Year: 2025
Authors: Ayton, D.(1)*;Hoque , S.(1);
(1)Whipps Cross University Hospital - Barts Health NHS Trust, Gastroenterology, London, United Kingdom;
1. Norman E, Hoque S. P185 Food avoidance and dietary restrictions in patients with Inflammatory Bowel Disease. J Crohns Colitis. 2024;18(Suppl 1) doi:10.1093/ecco-jcc/jjad212.0315.
2. World Gastroenterology Organisation. Test for Diagnosing IBS. Published 2009. Available at: https://www.worldgastroenterology.org/UserFiles/file/wdhd-2009-test-for-diagnosing-ibs.pdf
P0216: PANoptosis-related genes can predict the progression of ulcerative colitis and colitis-associated colorectal cancer.ECCO'25Year: 2025
Authors: Li, Y.(1)*;Zheng, S.(1);Yan, Q.(1);Zhong, X.(1);
(1)The Affiliated Hospital of Southwest Medical University, Department of Gastroenterology, Luzhou, China;
Nature. 2007;448(7152):427-434. doi:10.1038/nature060052. Jess T, Rungoe C, Peyrin L. Risk of Colorectal Cancer in Patients With Ulcerative Colitis: A Meta-analysis of Population-Based Cohort Studies. 2012;10(6).3. Shin J, Baek GH, Cha B, et al. Complementary Therapeutic Effect of Fecal Microbiota Transplantation in Ulcerative Colitis after the Response to Anti-Tumor Necrosis Factor Alpha Agent Was Lost: A Case Report. Published online 2024. doi:10.3390/biomedicines12040800Front Cell Infect Microbiol. 2019;9:406. doi:10.3389/fcimb.2019.00406J Immunol. 2022;209(9):1625-1633. doi:10.4049/jimmunol.2200508World J Gastroenterol. 2014;20(44):16389. doi:10.3748/wjg.v20.i44.16389
P0217: Colonic stromal cells are a source of sphingosine-1-phosphate and may be defining responsiveness to sphingosine-1-phosphate receptor modulators in Ulcerative ColitisECCO'25Year: 2025
Authors: Drygiannakis, I.(1,2)*;Damianaki, A.(1);Filidou, E.(3);Theodoraki, E.(2);Coucoutsi, C.(2);Foteinogiannopoulou, K.(2);Spathakis, M.(3);Kandilogiannakis, L.(3);Dovrolis, N.(3);Kolios, G.(3);Valatas, V.(1,2);Koutroubakis, I.(1,2);
(1)University of Crete, School of Medicine, Heraklion, Greece;(2)Heraklion University Hospital, Department of Gastroenterology, Heraklion, Greece;(3)Democritus University of Thrace, Department of Medicine, Alexandroupolis, Greece;
P0218: Dietary Inflammatory Index and disease activity in patients with IBD: is there an association? A Preliminary AnalysisECCO'25Year: 2025
Authors: Soares, C.(1)*;Martins, D.(2);Sousa, P.(2);Cancela, E.(2);Martins, S.(3);Torres, D.(4);Ministro, P.(2);
(1)Centro Hospitalar Tondela Viseu, Gastroenterology, VISEU, Portugal;(2)Centro Hospitalar Tondela-Viseu, Gastroenterology, Viseu, Portugal;(3)University of Porto, Institute of Public Health, Porto, Portugal;(4)Faculty of Nutrition and Food Sciences, University of Porto, Porto, Portugal;
1 Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):56-66.
2 Adolph TE, Zhang J. Diet fuelling inflammatory bowel diseases: preclinical and clinical concepts. Gut. 2022 Dec;71(12):2574-2586.
3 Adolph TE, Meyer M, Schwärzler J, Mayr L, Grabherr F, Tilg H. The metabolic nature of inflammatory bowel diseases. Nat Rev Gastroenterol Hepatol. 2022 Dec;19(12):753-767. 4 Sh Shivappa N, Steck SE, Hurley TG, Hussey JR, Hébert JR. Designing and developing a literature-derived, population-based dietary inflammatory index. Public Health Nutr. 2014 Aug;17(8):1689-96.
P0219: The role of IP10 as a possible biomarker of Short Bowel Syndrome: a preliminary studyECCO'25Year: 2025
Authors: Pane, C.(1)*;Di Mattia, M.(1);Petito, V.(2);Foscarini, E.(3);Profeta, F.(3);Becherucci, G.(3);Masi, L.(2);Troisi, S.(1,2);Emoli, V.(2);Rondinone, B.(2);Turchini, L.(3);Gasbarrini, A.(2,3,4);Papa, A.(3,4);Scaldaferri, F.(2,3,4);Lopetuso, L.R.(1,2,3,5);
(1)Center for Advanced Studies and Technology CAST- “G. d’Annunzio” University of Chieti-Pescara, Medicina e Scienze dell'Invecchiamento, Chieti, Italy;(2)CeMAD Translational Research Laboratories- Digestive Disease Center CeMAD- Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Department of Medical and Surgical Sciences, Rome, Italy;(3)IBD Unit- Digestive Disease Center CeMAD- Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Department of Medical and Surgical Sciences, Rome, Italy;(4)Catholic University of the Sacred Heart, Department of Translational Medicine and Surgery, Rome, Italy;(5)“G. d’Annunzio” University of Chieti-Pescara, Department of Medicine and Ageing Sciences, Chieti, Italy;
- Massironi S, Cavalcoli F, Rausa E, Invernizzi P, Braga M, Vecchi M. Understanding short bowel syndrome: Current status and future perspectives. Dig Liver Dis. 2020;52(3):253-261. doi:10.1016/j.dld.2019.11.013
- Pironi L, Konrad D, Brandt C, et al. Clinical classification of adult patients with chronic intestinal failure due to benign disease: An international multicenter cross-sectional survey. Clin Nutr. 2018;37(2):728-738. doi:10.1016/j.clnu.2017.04.013
- Limketkai BN, Parian AM, Shah ND, Colombel JF. Short Bowel Syndrome and Intestinal Failure in Crohn's Disease. Inflamm Bowel Dis. 2016;22(5):1209-1218. doi:10.1097/MIB.0000000000000698
- Devito A. Alpha chemokines in Crohn's disease. Clin Ter. 2015;166(2):e114-e117. doi:10.7417/CT.2015.1832
Fundings: 2.1 "Rafforzamento e potenziamento della ricerca biomedica del SSN", finanziato dall’Unione europea – NextGenerationEU, CUP C53C22001140007. 2022 PNRR Project "Changing the future of intestinal failure in intestinal chronic inflammation: towards innovative predictive factors and therapeutic targets" code: PNRR-MAD-2022-12376791.
P0220: Anti-TNFα, anti-integrin α4β7 and anti-IL23p19 biologic treatment dose optimization in a dextran sodium sulphate (DSS)-induced colitis mouse modelECCO'25Year: 2025
Authors: Suarez-Trujillo, F.(1)*;Orejudo, M.(1);Soleto, I.(1);Ramírez, C.(1);Baldán-Martín, M.(1);Martínez, P.J.(1);Gordillo-Vélez, C.H.(2);Cibrián, D.(3);P. Gisbert*, J.(1);Chaparro*, M.(1);
(1)Servicio de Aparato Digestivo. Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD- Madrid. Spain, Servicio de Aparato Digestivo, Madrid, Spain;(2)Servicio de Anatomía Patológica. Hospital Universitario de La Princesa- Madrid- Spain, Servicio de Anatomía Patológica, Madrid, Spain;(3)Servicio de Inmunología. Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Centro Nacional de Investigaciones Cardiovasculares CNIC- and Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares CIBERCV- Madrid. Spain, Servicio de Inmunología, Madrid, Spain; *These authors share senior authorship
P0221: The role of caffeine and its metabolites in the modulation of intestinal inflammation and epithelial barrier integrityECCO'25Year: 2025
Authors: Kulokiene, U.(1)*;Inciuraite, R.(1);Butaite, G.(1);Salteniene, V.(1);Kiudelis, V.(2);Jonaitis, L.V.(2);Kiudelis, G.(2);Kupcinskas, J.(2);Skieceviciene, J.(1);
(1)Lithuanian University of Health Sciences, Institute for Digestive Research, Kaunas, Lithuania;(2)Lithuanian University of Health Sciences, Institute for Digestive Research and Department of Gastroenterology, Kaunas, Lithuania;
Reddy V. S. et al. (2024) Pharmacology of caffeine and its effects on the human body. European Journal of Medicinal Chemistry Reports, 10 (100138). https://doi.org/10.1016/j.ejmcr.2024.100138.
P0222: Predicting corticosteroid failure in Acute Severe Ulcerative Colitis at admission using the ADMIT-ASC score.ECCO'25Year: 2025
Authors: Chan, P.(1)*;Ajmera, R.(1);Thin, L.(1,2);
(1)Fiona Stanley Hospital, Department of Gastroenterology, Murdoch, Australia;(2)Harry Perkins Institute of Medical Research, IBD Clinical Trials Unit, Murdoch, Australia;
[1] Adams, A., Gupta, V., Mohsen, W., Chapman, T. P., Subhaharan, D., Ramaswamy, P. K., ... & Satsangi, J. (2023). Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response. Gut, 72(3), 433-442.Chicago
[2] Ho, G. T., Mowat, C., Goddard, C. J. R., Fennell, J. M., Shah, N. B., Prescott, R. J., & Satsangi, J. (2004). Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second‐line medical therapy or surgery. Alimentary pharmacology & therapeutics, 19(10), 1079-1087.
P0223: In Vitro Fertilization in Women with Inflammatory Bowel Disease – Clinical Characteristics and OutcomesECCO'25Year: 2025
Authors: Ashkenazi, A.(1)*;Ron, Y.(2);Skornick-Rapaport, A.(2);Leibovitzh, H.(2);Thurm, T.(2);Hirsch, A.(2);Maharshak, N.(2);Cohen, N.A.(2);
(1)Tel Aviv Sourasky Medical Center - Ichilov, IBD center- Department of Gastroenterology and Liver Disesaes, Tel-Aviv, Israel;(2)Tel Aviv Sourasky Medical Center - Ichilov, IBD Center- Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel;
P0224: Learning Curve in Intestinal Ultrasound: Advancing from Basic Skills to Advanced Competencies – Insights from the IUS IG-IBD (Italian Group for the Study of Inflammatory Bowel Disease) Master ProgramECCO'25Year: 2025
Authors: Bezzio, C.(1);Pitoni, D.(2);Ribaldone, D.G.(2);Vernero, M.(2)*;Castiglione, F.(3);Rispo, A.(3);Saibeni, S.(4);Maconi, G.(5);Terracciano, F.(6);Bossa, F.(7);Allocca, M.(8);Furfaro, F.(8);Calabrese, E.(9);Zorzi, F.(9);Fraquelli, M.(10);Caprioli, F.(10);Rizzello, F.(11);Mazzotta, E.(11);Orlando, A.(12);Grova, M.(12);Massironi, S.(8);Viganò, C.(13);Armuzzi, A.(1);
(1)IRCCS Humanitas Research Hospital, Gastroenterology, Milan, Italy;(2)City of Health and Science University Hospital, Gastroenterology, Turin, Italy;(3)Azienda Ospedaliera Universitaria Policlinico Federico II, Gastroenterology, Naples, Italy;(4)ASST Rhodense, Gastroenterology, Rho, Italy;(5)ASST Fatebenefratelli Sacco, Gastroenterology, Milan, Italy;(6)Ospedale Casa Sollievo della Sofferenza, Gastroenterology, San Giovanni Rotondo, Italy;(7)Casa Sollievo della Sofferenza, Gastroenterology, San Giovanni Rotondo, Italy;(8)IRCCS Ospedale San Raffaele, Gastroenterology, Milan, Italy;(9)Policlinico Tor Vergata, Gastroenterology, Rome, Italy;(10)Policlinico di Milano Ospedale Maggiore, Gastroenterology, Milan, Italy;(11)Policlinico S. Orsola - Malpighi, Gastroenterology, Bologna, Italy;(12)Ospedali Riuniti Villa Sofia - Cervello, Gastroenterology, Palermo, Italy;(13)IRCCS San Gerardo dei Tintori, Gastroenterology, Monza, Italy;
P0225: Histone Serotonylation (H3Q5ser): A Novel Epigenetic Signature in Crohn’s Disease PathogenesisECCO'25Year: 2025
Authors: Li, J.(1,2)*;Overberg, K.(1,2);Metselaar, P.(1,2);te Velde, A.(1,2);Löwenberg, M.(3);D'Haens, G.(3);Derikx, J.(4);de Jonge, W.(1,2,5);Ghiboub, M.(1,2,4);
(1)Tytgat Institute for Liver and Intestinal Research- Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam University Medical Center- University of Amsterdam, Amsterdam, The Netherlands;(2)Amsterdam Gastroenterology Endocrinology Metabolism Institute, Amsterdam University Medical Center, Amsterdam, The Netherlands;(3)Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands;(4)Emma Children's Hospital- Pediatric Surgery, Amsterdam University Medical Center- University of Amsterdam, Amsterdam, The Netherlands;(5)Department of Surgery, University of Bonn, Bonn, Germany;
1- Ghiboub M et al. Sustained Diet-Induced Remission in Pediatric Crohn's Disease Is Associated With Kynurenine and Serotonin Pathways. Inflamm Bowel Dis. 2023 Jan 13:izac262. doi: 10.1093/ibd/izac262. Epub ahead of print. PMID: 36637175.
2- Hatamnejad MR, Baradaran Ghavami S, Shirvani M, Asghari Ahmadabad M, Shahrokh S, Farmani M, Sherkat G, Asadzadeh Aghdaei H, Zali MR. Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice. Front Immunol. 2022 Oct 6;13:980189. doi: 10.3389/fimmu.2022.980189. PMID: 36275739; PMCID: PMC9583131.
3- Farrelly LA et al. Histone serotonylation is a permissive modification that enhances TFIID binding to H3K4me3. Nature. 2019 Mar;567(7749):535-539. doi: 10.1038/s41586-019-1024-7. Epub 2019 Mar 13. PMID: 30867594; PMCID: PMC6557285.
4- Jeong EM, Son YH, Choi Y, Kim JH, Lee JH, Cho SY, Kim IG. Transglutaminase 2 is dispensable but required for the survival of mice in dextran sulfate sodium-induced colitis. Exp Mol Med. 2016 Nov 4;48(11):e267. doi: 10.1038/emm.2016.95. PMID: 27811936; PMCID: PMC5133373.
P0226: Postoperative recurrence after a definitive ostomy in Crohn's disease. A nationwide retrospective series from the Eneida registry.ECCO'25Year: 2025
Authors: Calafat Sard, M.(1)*;Mañosa, M.(2);Fernández-Clotet, A.(3);Pasanau, L.(4);Matallana , V.(5);Iglesias, E.(6);Hernández-Camba, A.(7);Ucha, P.(8);Nos, P.(9);Barrio , J.(10);Gutiérrez, A.(11);Merino, V.(12);Barreiro-de Acosta, M.(13);Cudero, L.(14);Casanova, M.J.(15);González-Muñoza, C.(16);Bujanda, L.(17);Varela, P.(18);Bermejo, F.(19);Torres, N.(20);Mesonero, F.(21);Calvet, X.(22);Rivas, C.(23);Pérez, C.(24);Alonso-Abreu, I.(25);Rodríguez-Lago, I.(26);Vega, P.(27);Zabana, Y.(28);Mora , M.(29); Busquets, D.(30);Rodríguez-Gutiérrez, C.(31);Torres, G.(32);Valldosera, G.(33);Ponferrada, Á.(34);Ceballos, D.(35);Martínez Pascual, C.(36);Jiménez, N.(37);Sampedro, M.(38);Irabien, M.(39);Domènech, E.(2);
(1)Hospital Universitari Germans Trias i Pujol- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD., Gastroenterology Department, Badalona, Spain;(2)Hospital Universitari Germans Trias i Pujol- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD., Gastroenterology, Badalona, Spain;(3)Hospital Clínic de Barcelona, Gastroenterology, Barcelona, Spain;(4)Hospital Universitari de Bellvitge, Gastroenterology, L’Hospitalet de Llobregat, Spain;(5)Hospital Universitario Puerta de Hierro, Gastroenterology, Majadahonda, Spain;(6)Hospital Universitario Reina Sofía de Córdoba- IMIBIC, Gastroenterology, Córdoba, Spain;(7)Hospital Universitario Nuestra Señora de Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain;(8)Hospital Álvaro Cunqueiro, Gastroenterology, Vigo, Spain;(9)Hospital Universitario y Politécnico de la Fe, Gastroenterology, Valencia, Spain;(10)Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Spain;(11)Hospital General Universitario Dr. Balmis de Alicante- ISABIAL - Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD., Gastroenterology, Alicante, Spain;(12)Hospital Clinic Universitari de Valencia, Gastroenterology, Valencia, Spain;(13)Hospital Clínico Universitario de Santiago – CHUS, Gastroenterology, Santiago de Compostela, Spain;(14)Hospital Universitario 12 de Octubre, Gastroenterology, Madrid, Spain;(15)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD., Gastroenterology, Madrid, Spain;(16)Hospital de la Santa Creu I Sant Pau, Gastroenterology, Barcelona, Spain;(17)Hospital Universitario Donostia- Biogipuzkoa Health Research Institute- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD., Gastroenterology, San Sebastian, Spain;(18)Hospital Universitario de Cabueñes, Gastroenterology, Gijón, Spain;(19)Hospital Universitario de Fuenlabrada, Gastroenterology, Fuenlabrada, Spain;(20)Hospital Universitario Arnau de Vilanova de Lleida, Gastroenterology, Lleida, Spain;(21)Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain;(22)Parc Taulí- Hospital Universitari- Institut d'Investigació i Innovació Parc Taulí. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD- Instituto de Salud Carlos II, Gastroenterology, Sabadell, Spain;(23)Hospital Universitario Marqués de Valdecilla, Gastroenterology, Santander, Spain;(24)Complejo Asistencial Universitario de Palencia, Gastroenterology, Palencia, Spain;(25)Hospital Universitario de Canarias, Gastroenterology, La Laguna, Spain;(26)Hospital Universitario de Galdakao, Gastroenterology, Galdakao, Spain;(27)Complexo Hospitalario Universitario de Ourense, Gastroenterology, Ourense, Spain;(28)Hospital Universitari Mútua de Terrassa - Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD., Gastroenterology, Terrassa, Spain;(29)Hospital de Manises, Gastroenterology, Valencia, Spain;(30)Hospital Universitari de Girona Doctor Josep Trueta, Gastroenterology, Girona, Spain;(31)Hospital Universitario de Navarra- IdiSNA, Gastroenterology, Pamplona, Spain;(32)Hospital General de Granollers, Gastroenterology, Granollers, Spain;(33)Hospital Universitario Joan XXIII de Tarragona, Gastroenterology, Tarragona, Spain;(34)Hospital Universitario Infanta Leonor, Gastroenterology, Madrid, Spain;(35)Hospital Universitario de Gran Canaria Dr. Negrín, Gastroenterology, Las Palmas de Gran Canaria, Spain;(36)Hospital Clínico Universitario Virgen de la Arrixaca, Gastroenterology, Murcia, Spain;(37)Hospital General Universitario de Elche, Gastroenterology, Elche, Spain;(38)Hospital de Mataró, Gastroenterology, Mataró, Spain;(39)Hospital Alfredo Espinosa, Gastroenterology, Urduliz, Spain; on behalf of the ENEIDA registry of GETECCU
P0227: Uncontrolled clinical activity and anti-TNF plus thiopurine combination therapy are predictive factors of 1-year infection risk following acute severe ulcerative colitis: AOCC and ANZIBDC collaboration studyECCO'25Year: 2025
Authors: Kim, S.J.(1)*;Kim, D.H.(2);Park, S.H.(3);Kim, K.O.(4);Jang, B.I.(4);Kim , D.S.(5);Lee, Y.J.(6);Song, E.M.(7);Lee, H.S.(8);Kim, E.S.(8);Yang, C.H.(9);Sagami, S.(10);Kobayashi, T.(10);Mak, J.(11);Liu, J.(12);Cao, Q.(12);Lin, C.C.(13);Lin, W.C.(14);Hsu, W.G.(15);Wei, S.C.(16);Rice, K.(17);An, Y.K.(17);Begun, J.(17);Ruddick-Collins, L.(18);G Fernandes, R.(17);Robert, G.(17);Vasudevan, A.(19);Zhang, J.(19);Brownson, A.(20);Ngoi, B.(21);Kate, L.(21);Haifer, C.(22);Bracken, L.M.L.(22);Swe, E.(23);Wright, E.(24);Clark, N.(24);Schildkraut, T.(24);Mahy, G.(23);Moore, G.(25);Garg, M.(26);
(1)College of Medicine- Chosun University, Internal Medicine, Gwangju, Korea- Republic Of;(2)Chonnam National University Hospital, Internal Medicine, Gwangju, Korea- Republic Of;(3)University of Ulsan College of Medicine- Asan Medical Center- Korea, Gastroenterology and Inflammatory Bowel Disease Center, Seoul, Korea- Republic Of;(4)Yeungnam University Hospital, Internal Medicine, Daegu, Korea- Republic Of;(5)Konyang University Hospital, Internal Medicine, Deajeon, Korea- Republic Of;(6)Keimyung University Hospital, Internal Medicine, Daegu, Korea- Republic Of;(7)Ewha Womans University Seoul Hospital, Internal Medicine, Seoul, Korea- Republic Of;(8)Kyungpook National University Hospital, Internal Medicine, Daegu, Korea- Republic Of;(9)Daegu catholic university chilgok catholic hospital, Internal Medicine, Daegu, Korea- Republic Of;(10)University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment- Kitasato, Tokyo, Japan;(11)The Chinese University of Hong Kong, Gastroenterology, Hong Kong, Hong Kong- China;(12)Sir Run Run Shaw Hospital- Zhejiang University School of Medicine- Center for Inflammatory Bowel Disease, Gastroenterology, Hangzhou, China;(13)Taipei Veterans General Hospital, Gastroenterology, Taipei, Taiwan;(14)Mackay Memorial Hospital, Gastroenterology, Taiwan, Taiwan;(15)Kaohsiung Medical University, Gastroenterology, Kaohsiung, Taiwan;(16)National Taiwan University Hospital- National Taiwan University, Internal Medicine, Taipei, Taiwan;(17)Mater Hospital, Gastroenterology, Brisbane, Australia;(18)Mater Research Institute- University of Queensland, Gastroenterology, Brisbane, Australia;(19)Eastern Health, Gastroenterology, Melbourne, Australia;(20)Te Whatu Ora – Southern- Dunedin Hospital, Gastroenterology, Dunedin, New Zealand;(21)Royal Adelaide Hospital, Gastroenterology, Adelaide, Australia;(22)St Vincent’s Hospital Sydney, Gastroenterology, Sydney, Australia;(23)Townsville University Hospital, Gastroenterology, Townsville, Australia;(24)St Vincent’s Hospital Melbourne, Gastroenterology, Melbourne, Australia;(25)Monash Health- and Monash University, Gastroenterology, Melbourne, Australia;(26)The Northern Hospital, Gastroenterology, Epping, Australia; On Behalf of IBD Research group in KASID AOCC and ANZIBDC
1. Solitano V, Facciorusso A, Jess T, et al. Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2023 Apr;21(4):907-921.e2
2. Kucharzik T, Ellul P, Greuter T, et al. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis. 2021 Jun 22;15(6):879-913.
3. Ahuja D, Luo J, Qi Y, et al. Impact of Treatment Response on Risk of Serious Infections in Patients With Crohn's Disease: Secondary Analysis of the PYRAMID Registry. Clin Gastroenterol Hepatol. 2024 Jun;22(6):1286-1294.e4.
P0228: Evolution of the IBD-Disability Index in a cohort of recently diagnosed CD patients: results from the prospective CROCO (Crohn´s Disease Cohort) StudyECCO'25Year: 2025
Authors: Buisson, A.(1)*;Bonnet-Dodel-, M.(2);Revés, J.(3);Burisch, J.(4,5,6);Madsen, G.R.(7);Arebi, N.(8,9);Fadra, A.(8);Vieujean, S.(10);Monin, L.(11);Cravo, M.(12);Duricova, D.(13,14,15);Ellul, P.(16);Kaimakliotis, I.(17);Sebastian, S.(18);Ordas, I.(19);Rodríguez-Lago, I.(20);Mocanu, I.(21);Hernandez, V.(22);Nachury, M.(23);Fumery, M.(24);Goldis, A.(25);Pedersen, N.(26);Conceição, D.(27);Barberio, B.(28);Guedes, A.(29);Ribeiro, R.(30);Ungaro, R.(31);Mary, J.Y.(32);Bigot, N.(32);Jérome Lambert, J.L.(32);Colombel, J.F.(33);Torres, J.(3);
(1)CHU Clermont - Ferrand- Clermont-Ferrand- France, IBD Unit, Clermont-Ferrand, France;(2)CHU Clermont - Ferrand, IBD Unit, Clermont-Ferrand, France;(3)Hospital Beatriz Ângelo, Division of Gastroenterology, Loures, Portugal;(4)Copenhagen University Hospital - Amager and Hvidrove, Gastrounit Medical Division, Hvidovre, Denmark;(5)University of Copenhagen, Department of Clinical Medicine- Faculty of Health and Medical Sciences- University of Copenhagen- Copenhagen- Denmark, Copenhagen, Denmark;(6)Copenhagen University Hospital - Amager and Hvidovre, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults, Hvidovre, Denmark;(7)Copenhagen University Hospital - Amager and Hvidovre, Gastrounit Medical Division, Hvidovre, Denmark;(8)St Mark's National Bowel Hospital, Department of IBD, London, United Kingdom;(9)Imperial College London, Department of Metabolism- Digestion and Reproduction, London- UK, United Kingdom;(10)University Hospital CHU of Liège, Hepato-Gastroenterology and Digestive Oncology, Liège, Belgium;(11)University Hospital CHU of Liège, Hepato-Gastroenterology and Digestive Oncology, Liége, Belgium;(12)Hospital da Luz- Luz Saúde, Division of Gastroenterology, Lisboa, Portugal;(13)ISCARE a.s., IBD Clinical and Research Clinic, Prague- Czech Republic, Czech Republic;(14)Institute for Clinical and Experimental Medicine, Department of Hepatogastroenterology, Prague, Czech Republic;(15)1st Faculty of Medicine- Chareles University, Institute of Pharmacology, Prague, Czech Republic;(16)Mater dei Hospital, Department of Gastroenterology, Msida, Malta;(17)American Gastroenterology Center, Gastroenterologie and Hepatologist, Strovolos- Cyprus, Cyprus;(18)Hull University Teaching Hospitals, IBD Research Unit- Department of Gastroenterology, Hull, United Kingdom;(19)Hospital Clinic Barcelona- IDIBAPS- CIBER-EHD, IBD Unit- Department of Gastroenterology, Barcelona, Spain;(20)Hospital Universitario de Galdakao- Biobizkaia Health Research Institute, Department of Gastroenterology, Galdakao, Spain;(21)Hospital Garcia de Orta, Department of Gastroenterology, Almada, Portugal;(22)Hospital Alvaro Cunqueiro, Gastroenterologie, Vigo, Spain;(23)Univ. Lille- Inserm- CHU Lille- U1286 - INFINITE, Institute for Translational Research in Inflammation, Lille, France;(24)CHU Amiens-Picardie Hôpital Sud, Department of Hepato - Gastroenterology, Amiens, France;(25)Algomed Policlinic, Gastroenterologie, Timisoara, Romania;(26)Slagelse Hospital, Gastroenterologie, Slagelse, Denmark;(27)Instituto Português de Oncologia, Division of Gastroenterology, Lisboa, Portugal;(28)University of Padua, Division of Gastroenterology- Department of Surgery- Oncology and Gastroenterology, Padua, Italy;(29)Hospital da Luz Learning Health- Luz Saúde- Lisboa- Portugal, Research Department, Lisboa, Portugal;(30)Hospital da Luz Learning Health- Luz Saúde, Resarch Department, Lisboa, Portugal;(31)Mount Sinai Hospital- New York, Department of Gastroenterology, New York, United States;(32)Centre of Research in Epidemiology and Statistics- UMR 1153- Inserm, ECSTRRA Unit, Paris, France;(33)Mount Sinai Hospital, Department of Gastroenterology, New York, United States; CROCO Study Group
1Le Berre, C., Peyrin-Biroulet, L., Sandborn, W. J., Colombel, J. F., Rubin, D., Chowers, Y., ... & Danese, S. (2021). Selecting end points for disease-modification trials in inflammatory bowel disease: the SPIRIT consensus from the IOIBD. Gastroenterology, 160(5), 1452-1460.
P0229: Evaluation of anorectal function and structure in patients with perianal Crohn's disease with a novel 3-D high-definition anorectal manometry technologyECCO'25Year: 2025
Authors: Lastiri, E.(1)*;Barber, C.(2);Serra, J.(2);Herrera, C.(1);Mayorga, L.(1);Robles, V.(1);Cespedes, E.(1);Serra, X.(1);Perez, Z.(1);Oller, E.(1);Borruel, N.(1);
(1)University Hospital Vall D´Hebron, Crohn and Colitis Unit - Gastroenterology Department, Barcelona, Spain;(2)University Hospital Vall D´Hebron, Neurogastroenterology and Motility Unit - Gastroenterology, Barcelona, Spain;
Eglinton TW, Barclay ML, Gearry RB, et al. The spectrum of perianal Crohn’s disease in apopulation-based cohort. Dis Colon Rectum 2012;55:773–7.
Felt-Bersma, R.J.F., Vlietstra, M.S., Vollebregt, P.F. et al. 3D high-resolution anorectal manometry in patients with perianal fistulas: comparison with 3D-anal ultrasound. BMC Gastroenterol 18, 44 (2018)
R Costache, A Dimitriu, A Les, C Gheorghe, P027 Anorectal Motility Disorders in Inflammatory Bowel Disease patients, Journal of Crohn's and Colitis, Volume 17, Issue Supplement_1, February 2023, Page i197
De Codes LMG, de Jesus ACC, de Codes JJG, Ferreira RF, da Silva Beda Sacramento C, da Cruz IDM, de Castro Ribeiro Fidelis F, de Carvalho AL, Motta MP, de Oliveira Alves C, Netto EM, Santana GO. Anorectal function and clinical characteristics associated with fecal incontinence in patients with Crohn's disease. J Crohns Colitis. 2023 Mar 23:jjad048
P0230: Prognostic factors and predictive model development for pediatric Inflammatory Bowel Disease with IL-10RA deficiency: A retrospective cohort study.ECCO'25Year: 2025
Authors: Shi, X.(1)*;Qian, L.(1);Wu, H.(1);Wang, L.(1);Ye, Z.(1);Dong, K.(2);Sun, S.(2);Zhai , X.(3);Qian, X.(3);Huang, Y.(1);
(1)Children's hospital of fudan university, Department of Gastroenterology, Shanghai, China;(2)Children's hospital of fudan university, Department of Pediatric Surgery, Shanghai, China;(3)Children's hospital of fudan university, Department of Hematology and Oncology, Shanghai, China;
